Company Destiny Pharma plc

Destiny Pharma plc is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late stage assets, NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.difficile infection (CDI) recurrence, which is the principal cause of hospital acquired infection in the United States, and XF-73 nasal gel, a proprietary drug targeting the prevention of postsurgical staphylococcal hospital infections including methicillin-resistant Staphylococcus aureus (MRSA). The Company’s earlier stage pipeline is focused on other indications including two, separate dermal programmes incorporating its XF platform. It is also collaborating with SporeGen on a novel SPOR-COV innate immune system boosting nasal spray for the prevention of COVID-19 and influenza.

Number of employees: 24